Which has preferable valuation & earnings, VTRS or GRFS?

Grifols has lower revenue, but higher earnings than Viatris. Viatris is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Viatris $14.30B 1.36 -$3.51B -$0.26 N/A Grifols $8.51B 0.57 $454.82M $0.19 37.68

Is VTRS or GRFS more profitable?

Grifols has a net margin of 5.54% compared to Viatris' net margin of -2.04%. Viatris' return on equity of 19.04% beat Grifols' return on equity. Company Net Margins Return on Equity Return on Assets Viatris -2.04% 19.04% 7.62% Grifols 5.54% 6.21% 2.39%

Does the media prefer VTRS or GRFS?

In the previous week, Viatris had 3 more articles in the media than Grifols. MarketBeat recorded 4 mentions for Viatris and 1 mentions for Grifols. Grifols' average media sentiment score of 1.38 beat Viatris' score of 0.72 indicating that Grifols is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viatris 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Grifols 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, GMAB or GRFS?

Genmab A/S has higher earnings, but lower revenue than Grifols. Genmab A/S is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Genmab A/S $3.72B 4.78 $963M $1.32 21.60 Grifols $8.51B 0.57 $454.82M $0.19 37.68

Is GMAB or GRFS more profitable?

Genmab A/S has a net margin of 21.05% compared to Grifols' net margin of 5.54%. Genmab A/S's return on equity of 15.34% beat Grifols' return on equity. Company Net Margins Return on Equity Return on Assets Genmab A/S 21.05% 15.34% 8.94% Grifols 5.54% 6.21% 2.39%

Does the media prefer GMAB or GRFS?

In the previous week, Genmab A/S had 4 more articles in the media than Grifols. MarketBeat recorded 5 mentions for Genmab A/S and 1 mentions for Grifols. Grifols' average media sentiment score of 1.38 beat Genmab A/S's score of 0.69 indicating that Grifols is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Genmab A/S 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Grifols 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, GRFS or ASND?

Grifols has higher revenue and earnings than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Grifols $8.51B 0.57 $454.82M $0.19 37.68 Ascendis Pharma A/S $865.78M 19.78 -$258M $8.67 31.66

Does the media refer more to GRFS or ASND?

In the previous week, Ascendis Pharma A/S had 5 more articles in the media than Grifols. MarketBeat recorded 6 mentions for Ascendis Pharma A/S and 1 mentions for Grifols. Grifols' average media sentiment score of 1.38 beat Ascendis Pharma A/S's score of 0.60 indicating that Grifols is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Grifols 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ascendis Pharma A/S 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, GRFS or BBIO?

Grifols has higher revenue and earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Grifols $8.51B 0.57 $454.82M $0.19 37.68 BridgeBio Pharma $502.08M 30.11 -$724.93M -$3.74 N/A

Does the media favor GRFS or BBIO?

In the previous week, BridgeBio Pharma had 7 more articles in the media than Grifols. MarketBeat recorded 8 mentions for BridgeBio Pharma and 1 mentions for Grifols. Grifols' average media sentiment score of 1.38 beat BridgeBio Pharma's score of 0.63 indicating that Grifols is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Grifols 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BridgeBio Pharma 2 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, AXSM or GRFS?

Grifols has higher revenue and earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Axsome Therapeutics $638.50M 19.69 -$183.17M -$3.73 N/A Grifols $8.51B 0.57 $454.82M $0.19 37.68

Is AXSM or GRFS more profitable?

Grifols has a net margin of 5.54% compared to Axsome Therapeutics' net margin of -26.59%. Grifols' return on equity of 6.21% beat Axsome Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Axsome Therapeutics -26.59% -267.16% -28.53% Grifols 5.54% 6.21% 2.39%

Does the media prefer AXSM or GRFS?

In the previous week, Axsome Therapeutics had 5 more articles in the media than Grifols. MarketBeat recorded 6 mentions for Axsome Therapeutics and 1 mentions for Grifols. Grifols' average media sentiment score of 1.38 beat Axsome Therapeutics' score of 0.75 indicating that Grifols is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Axsome Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Grifols 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Grifols (GRFS) Competitors

$7.16 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$7.16 0.00 (-0.07%)

As of 07/2/2026 04:10 PM Eastern

Compare

GRFS vs. VTRS, GMAB, ASND, BBIO, and AXSM

Should you buy Grifols stock or one of its competitors? MarketBeat compares Grifols with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Grifols include Viatris (VTRS), Genmab A/S (GMAB), Ascendis Pharma A/S (ASND), BridgeBio Pharma (BBIO), and Axsome Therapeutics (AXSM). These companies are all part of the "pharmaceutical products" industry.

How does Grifols compare to Viatris?

Viatris (NASDAQ:VTRS) and Grifols (NASDAQ:GRFS) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends, earnings and media sentiment.

Grifols has a net margin of 5.54% compared to Viatris' net margin of -2.04%. Viatris' return on equity of 19.04% beat Grifols' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viatris	-2.04%	19.04%	7.62%
Grifols	5.54%	6.21%	2.39%

Viatris has a beta of 0.91, suggesting that its share price is 9% less volatile than the broader market. Comparatively, Grifols has a beta of 0.67, suggesting that its share price is 33% less volatile than the broader market.

Viatris pays an annual dividend of $0.48 per share and has a dividend yield of 2.9%. Grifols pays an annual dividend of $0.22 per share and has a dividend yield of 3.1%. Viatris pays out -184.6% of its earnings in the form of a dividend. Grifols pays out 115.8% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.

Viatris presently has a consensus target price of $17.50, indicating a potential upside of 4.79%. Grifols has a consensus target price of $10.00, indicating a potential upside of 39.66%. Given Grifols' higher probable upside, analysts plainly believe Grifols is more favorable than Viatris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viatris	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57
Grifols	2 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Grifols has lower revenue, but higher earnings than Viatris. Viatris is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viatris	$14.30B	1.36	-$3.51B	-$0.26	N/A
Grifols	$8.51B	0.57	$454.82M	$0.19	37.68

79.9% of Viatris shares are held by institutional investors. 0.3% of Viatris shares are held by insiders. Comparatively, 0.2% of Grifols shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Viatris had 3 more articles in the media than Grifols. MarketBeat recorded 4 mentions for Viatris and 1 mentions for Grifols. Grifols' average media sentiment score of 1.38 beat Viatris' score of 0.72 indicating that Grifols is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viatris	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Grifols	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Viatris beats Grifols on 11 of the 18 factors compared between the two stocks.

How does Grifols compare to Genmab A/S?

Genmab A/S (NASDAQ:GMAB) and Grifols (NASDAQ:GRFS) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, media sentiment, earnings, risk and analyst recommendations.

7.1% of Genmab A/S shares are owned by institutional investors. 1.5% of Genmab A/S shares are owned by insiders. Comparatively, 0.2% of Grifols shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Genmab A/S has a beta of 0.84, meaning that its stock price is 16% less volatile than the broader market. Comparatively, Grifols has a beta of 0.67, meaning that its stock price is 33% less volatile than the broader market.

In the previous week, Genmab A/S had 4 more articles in the media than Grifols. MarketBeat recorded 5 mentions for Genmab A/S and 1 mentions for Grifols. Grifols' average media sentiment score of 1.38 beat Genmab A/S's score of 0.69 indicating that Grifols is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genmab A/S	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Grifols	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Genmab A/S has a net margin of 21.05% compared to Grifols' net margin of 5.54%. Genmab A/S's return on equity of 15.34% beat Grifols' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genmab A/S	21.05%	15.34%	8.94%
Grifols	5.54%	6.21%	2.39%

Genmab A/S presently has a consensus target price of $38.21, indicating a potential upside of 34.04%. Grifols has a consensus target price of $10.00, indicating a potential upside of 39.66%. Given Grifols' higher possible upside, analysts plainly believe Grifols is more favorable than Genmab A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genmab A/S	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75
Grifols	2 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Genmab A/S has higher earnings, but lower revenue than Grifols. Genmab A/S is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genmab A/S	$3.72B	4.78	$963M	$1.32	21.60
Grifols	$8.51B	0.57	$454.82M	$0.19	37.68

Summary

Genmab A/S beats Grifols on 13 of the 17 factors compared between the two stocks.

How does Grifols compare to Ascendis Pharma A/S?

Grifols (NASDAQ:GRFS) and Ascendis Pharma A/S (NASDAQ:ASND) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, profitability, risk, media sentiment, analyst recommendations, dividends, earnings and institutional ownership.

In the previous week, Ascendis Pharma A/S had 5 more articles in the media than Grifols. MarketBeat recorded 6 mentions for Ascendis Pharma A/S and 1 mentions for Grifols. Grifols' average media sentiment score of 1.38 beat Ascendis Pharma A/S's score of 0.60 indicating that Grifols is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Grifols	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ascendis Pharma A/S	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ascendis Pharma A/S has a net margin of 57.87% compared to Grifols' net margin of 5.54%. Grifols' return on equity of 6.21% beat Ascendis Pharma A/S's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Grifols	5.54%	6.21%	2.39%
Ascendis Pharma A/S	57.87%	N/A	-8.37%

Grifols has a beta of 0.67, suggesting that its stock price is 33% less volatile than the broader market. Comparatively, Ascendis Pharma A/S has a beta of 0.37, suggesting that its stock price is 63% less volatile than the broader market.

Grifols has higher revenue and earnings than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Grifols	$8.51B	0.57	$454.82M	$0.19	37.68
Ascendis Pharma A/S	$865.78M	19.78	-$258M	$8.67	31.66

Grifols presently has a consensus price target of $10.00, indicating a potential upside of 39.66%. Ascendis Pharma A/S has a consensus price target of $295.39, indicating a potential upside of 7.61%. Given Grifols' higher possible upside, research analysts clearly believe Grifols is more favorable than Ascendis Pharma A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Grifols	2 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Ascendis Pharma A/S	1 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

Grifols beats Ascendis Pharma A/S on 8 of the 15 factors compared between the two stocks.

How does Grifols compare to BridgeBio Pharma?

Grifols (NASDAQ:GRFS) and BridgeBio Pharma (NASDAQ:BBIO) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, profitability, analyst recommendations, dividends, media sentiment and risk.

Grifols has a beta of 0.67, meaning that its share price is 33% less volatile than the broader market. Comparatively, BridgeBio Pharma has a beta of 0.95, meaning that its share price is 5% less volatile than the broader market.

Grifols presently has a consensus target price of $10.00, suggesting a potential upside of 39.66%. BridgeBio Pharma has a consensus target price of $92.90, suggesting a potential upside of 20.35%. Given Grifols' higher possible upside, research analysts clearly believe Grifols is more favorable than BridgeBio Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Grifols	2 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	21 Buy rating(s)	0 Strong Buy rating(s)	2.83

Grifols has higher revenue and earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Grifols	$8.51B	0.57	$454.82M	$0.19	37.68
BridgeBio Pharma	$502.08M	30.11	-$724.93M	-$3.74	N/A

In the previous week, BridgeBio Pharma had 7 more articles in the media than Grifols. MarketBeat recorded 8 mentions for BridgeBio Pharma and 1 mentions for Grifols. Grifols' average media sentiment score of 1.38 beat BridgeBio Pharma's score of 0.63 indicating that Grifols is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Grifols	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BridgeBio Pharma	2 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Grifols has a net margin of 5.54% compared to BridgeBio Pharma's net margin of -124.42%. Grifols' return on equity of 6.21% beat BridgeBio Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Grifols	5.54%	6.21%	2.39%
BridgeBio Pharma	-124.42%	N/A	-65.81%

99.9% of BridgeBio Pharma shares are owned by institutional investors. 0.2% of Grifols shares are owned by company insiders. Comparatively, 14.2% of BridgeBio Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Grifols beats BridgeBio Pharma on 9 of the 16 factors compared between the two stocks.

How does Grifols compare to Axsome Therapeutics?

Axsome Therapeutics (NASDAQ:AXSM) and Grifols (NASDAQ:GRFS) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, risk, profitability, dividends, earnings and media sentiment.

Grifols has higher revenue and earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Axsome Therapeutics	$638.50M	19.69	-$183.17M	-$3.73	N/A
Grifols	$8.51B	0.57	$454.82M	$0.19	37.68

In the previous week, Axsome Therapeutics had 5 more articles in the media than Grifols. MarketBeat recorded 6 mentions for Axsome Therapeutics and 1 mentions for Grifols. Grifols' average media sentiment score of 1.38 beat Axsome Therapeutics' score of 0.75 indicating that Grifols is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Axsome Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Grifols	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Grifols has a net margin of 5.54% compared to Axsome Therapeutics' net margin of -26.59%. Grifols' return on equity of 6.21% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Axsome Therapeutics	-26.59%	-267.16%	-28.53%
Grifols	5.54%	6.21%	2.39%

Axsome Therapeutics currently has a consensus price target of $258.95, suggesting a potential upside of 5.99%. Grifols has a consensus price target of $10.00, suggesting a potential upside of 39.66%. Given Grifols' higher probable upside, analysts clearly believe Grifols is more favorable than Axsome Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Axsome Therapeutics	1 Sell rating(s)	0 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	2.95
Grifols	2 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

81.5% of Axsome Therapeutics shares are owned by institutional investors. 20.6% of Axsome Therapeutics shares are owned by insiders. Comparatively, 0.2% of Grifols shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Axsome Therapeutics has a beta of 0.6, indicating that its stock price is 40% less volatile than the broader market. Comparatively, Grifols has a beta of 0.67, indicating that its stock price is 33% less volatile than the broader market.

Summary

Grifols beats Axsome Therapeutics on 10 of the 17 factors compared between the two stocks.

Get Grifols News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GRFS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GRFS vs. The Competition

Export

Metric	Grifols	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$4.87B	$3.10B	$7.18B	$12.48B
Dividend Yield	3.06%	2.05%	2.66%	6.51%
P/E Ratio	37.68	20.06	28.02	24.70
Price / Sales	0.57	357.03	535.36	97.93
Price / Cash	5.06	57.49	49.26	57.09
Price / Book	0.57	4.32	10.96	6.46
Net Income	$454.82M	$64.45M	$3.57B	$337.01M
7 Day Performance	-3.57%	2.97%	2.12%	1.69%
1 Month Performance	-6.28%	6.83%	5.25%	3.81%
1 Year Performance	-21.10%	29.07%	33.29%	23.90%

Grifols Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GRFS Grifols	4.5078 of 5 stars	$7.16 flat	$10.00 +39.7%	-21.1%	$4.87B	$8.51B	37.68	25,247	News Coverage Positive News High Trading Volume
VTRS Viatris	2.7908 of 5 stars	$16.23 -0.6%	$17.50 +7.8%	+80.5%	$19.02B	$14.56B	N/A	30,000	Gap Down
GMAB Genmab A/S	4.7856 of 5 stars	$26.02 -0.4%	$37.93 +45.8%	+39.7%	$16.29B	$3.90B	19.71	3,029	Analyst Forecast
ASND Ascendis Pharma A/S	4.1402 of 5 stars	$263.70 +1.1%	$295.39 +12.0%	+57.7%	$16.26B	$814.57M	30.42	1,189	Analyst Upgrade
BBIO BridgeBio Pharma	2.7921 of 5 stars	$72.01 +2.5%	$92.90 +29.0%	+76.6%	$13.76B	$502.08M	N/A	400	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GRFS) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Grifols (GRFS) Competitors

GRFS vs. VTRS, GMAB, ASND, BBIO, and AXSM

How does Grifols compare to Viatris?

Summary

How does Grifols compare to Genmab A/S?

Summary

How does Grifols compare to Ascendis Pharma A/S?

Summary

How does Grifols compare to BridgeBio Pharma?

Summary

How does Grifols compare to Axsome Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GRFS vs. The Competition

Grifols Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Grifols (GRFS) Competitors

GRFS vs. VTRS, GMAB, ASND, BBIO, and AXSM

How does Grifols compare to Viatris?

Is VTRS or GRFS more profitable?

Which has more volatility and risk, VTRS or GRFS?

Is VTRS or GRFS a better dividend stock?

Do analysts recommend VTRS or GRFS?

Which has preferable valuation & earnings, VTRS or GRFS?

Do insiders & institutionals have more ownership in VTRS or GRFS?

Does the media prefer VTRS or GRFS?

Summary

How does Grifols compare to Genmab A/S?

Do institutionals & insiders believe in GMAB or GRFS?

Which has more volatility and risk, GMAB or GRFS?

Does the media prefer GMAB or GRFS?

Is GMAB or GRFS more profitable?

Do analysts prefer GMAB or GRFS?

Which has preferable valuation and earnings, GMAB or GRFS?

Summary

How does Grifols compare to Ascendis Pharma A/S?

Does the media refer more to GRFS or ASND?

Is GRFS or ASND more profitable?

Which has more volatility and risk, GRFS or ASND?

Which has higher valuation and earnings, GRFS or ASND?

Do analysts prefer GRFS or ASND?

Summary

How does Grifols compare to BridgeBio Pharma?

Which has more risk & volatility, GRFS or BBIO?

Do analysts recommend GRFS or BBIO?

Which has preferable earnings and valuation, GRFS or BBIO?

Does the media favor GRFS or BBIO?

Is GRFS or BBIO more profitable?

Do institutionals & insiders hold more shares of GRFS or BBIO?

Summary

How does Grifols compare to Axsome Therapeutics?

Which has preferable valuation & earnings, AXSM or GRFS?

Does the media prefer AXSM or GRFS?

Is AXSM or GRFS more profitable?

Do analysts prefer AXSM or GRFS?

Do institutionals and insiders hold more shares of AXSM or GRFS?

Which has more volatility and risk, AXSM or GRFS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GRFS vs. The Competition

Grifols Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools